Company Analysis Ascentage Pharma Group International
1. Summary
Advantages
- Price (38.8 HK$) is less than fair price (45.38 HK$)
- The stock's return over the last year (65.98%) is higher than the sector average (-28.99%).
- Current debt level 71.59% is below 100% and has decreased over 5 years from 170.37%.
Disadvantages
- Dividends (0%) are below the sector average (2.43%).
- The company's current efficiency (ROE=-394.66%) is lower than the sector average (ROE=5.19%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Ascentage Pharma Group International | Healthcare | Index | |
|---|---|---|---|
| 7 days | -7.2% | -1% | -1.4% |
| 90 days | 23.7% | -4% | 12.5% |
| 1 year | 66% | -29% | 18.3% |
6855 vs Sector: Ascentage Pharma Group International has outperformed the "Healthcare" sector by 94.98% over the past year.
6855 vs Market: Ascentage Pharma Group International has outperformed the market by 47.69% over the past year.
Stable price: 6855 is not significantly more volatile than the rest of the market on "Hong Kong Exchanges" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 6855 with weekly volatility of 1.27% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (38.8 HK$) is lower than the fair price (45.38 HK$).
Price not significantly lower than the fair price: The current price (38.8 HK$) is slightly lower than the fair price by 17%.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (35.42).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (26.67).
4.3. P/BV
P/BV vs Sector: The company's P/BV (95.34) is higher than that of the sector as a whole (3.68).
P/BV vs Market: The company's P/BV (95.34) is higher than that of the market as a whole (-11.94).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (30.33) is higher than that of the sector as a whole (7.59).
P/S vs Market: The company's P/S indicator (30.33) is higher than that of the market as a whole (2.77).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-8.05) is lower than that of the sector as a whole (2.91).
EV/Ebitda vs Market: The company's EV/Ebitda (-8.05) is lower than that of the market as a whole (9.94).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -7.5% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-7.5%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-0.8799%).
5.4. ROE
ROE vs Sector: The company's ROE (-394.66%) is lower than that of the sector as a whole (5.19%).
ROE vs Market: The company's ROE (-394.66%) is lower than that of the market as a whole (6.3%).
5.5. ROA
ROA vs Sector: The company's ROA (-34.73%) is lower than that of the sector as a whole (3.47%).
ROA vs Market: The company's ROA (-34.73%) is lower than that of the market as a whole (3.39%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (0%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '2.43%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
